ClinVar Miner

Submissions for variant NM_014363.6(SACS):c.9311del (p.Thr3104fs)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV003324177 SCV004029094 pathogenic Charlevoix-Saguenay spastic ataxia 2023-07-20 criteria provided, single submitter clinical testing Variant summary: SACS c.9311delC (p.Thr3104AsnfsX23) results in a premature termination codon in the last exon that is not expected to result in nonsense mediated decay (NMD), but is predicted to cause a large truncation of the encoded protein. Variants downstream of this position have been classified as pathogenic by our laboratory (e.g., c.10906C>T (p.Arg3636X)). The variant was absent in 250710 control chromosomes. To our knowledge, no occurrence of c.9311delC in individuals affected with Autosomal Recessive Spastic Ataxia Of Charlevoix-Saguenay and no experimental evidence demonstrating its impact on protein function have been reported. No submitters have cited clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.